Learn how eClinical solutions can be effectively leveraged to create patient-centric and decentralized trials.
In 2020 we saw fast startup timelines for clinical trials and adaptations to trial designs to adjust to COVID-19. Regulatory authorities formulated more guidelines around decentralized trials, and while some sponsors capitalized on previous experiences, many used a decentralized model for the first time. If we’ve learned anything from 2020, it’s that direct-to-patient logistics has become a vital and viable solution for clinical trial sponsors.
For 2021 and beyond, it’s all about building more inclusive and patient-focused trials. So how can sponsors better incorporate the patient voice into their trials? How do we see decentralized trial capabilities expanding in the coming months to support this new era?
What You Will Learn
- How partnerships with best-in-class technology companies will safeguard against the year’s coming challenges
- Why patient centricity will no longer be considered an industry buzzword
- How direct-to-patient logistics helps enable other complex trial designs and increases inclusivity
- How eClinical solutions such as IRT, eConsent, and eCOA can create lasting impacts in productivity and patient engagement